BC Partners acquires Pharmathen

The deal gives the company an enterprise value of around €500m, unquote" understands.

As part of the transaction, Pharmathen’s founders will retain a minority stake in the business, with BC Partners picking up around 80% of the company’s shares, according to a source close to the deal.

The GP's capital was drawn from its ninth vehicle, a 2010-vintage fund which held its final close on its hard-cap of €6.5bn in February 2012.

Following completion of the deal, Pharmathen will look to expand internationally through a buy-and-build growth strategy.

Pharmathen is BC Partners' second portfolio company in the pharmaceutical sector, having previously acquired German business Aenova in a secondary buyout from Bridgepoint. The GP also has a stake in Synlab, a German laboratory diagnostic services company.

Company
Founded in 1969 and headquartered in Athens, Pharmathen develops, produces and licenses generic pharmaceutical products. The business has a headcount of around 1,000 across three laboratories and two manufacturing facilities. 

In 2014, Pharmathen generated a turnover of €180m. It has approximately 180 trade clients and exports its products to 80 countries.

People
Nikos Stathopoulos is managing partner at BC Partners. Vassilios Katsos is president and CEO of Pharmathen.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Southern Europe
• Healthcare
• Greece
• BC Partners
• Unq2015July